We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

76 hedge funds and large institutions have $31.4M invested in Merrimack Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

363% more call options, than puts

Call options by funds: $1.63M | Put options by funds: $352K

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

6% less funds holding

Funds holding: 81 → 76 (-5)

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

49% less capital invested

Capital invested by funds: $61.4M → $31.4M (-$30M)

Holders
76
Holders Change
-5
Holders Change %
-6.17%
% of All Funds
1.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
21
Reduced
20
Closed
20
Calls
$1.63M
Puts
$352K
Net Calls
+$1.28M
Net Calls Change
+$1.03M

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$9.37M
2
NM
Newtyn Management
New York
+$4.16M
3
WIM
Wittenberg Investment Management
Massachusetts
+$1.1M
4
Goldman Sachs
Goldman Sachs
New York
+$906K
5
JGC
J. Goldman & Co
New York
+$844K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.2M
2
BlackRock
BlackRock
New York
-$4.66M
3
Franklin Resources
Franklin Resources
California
-$2.98M
4
Deutsche Bank
Deutsche Bank
Germany
-$2.01M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
26
Element Capital Management
New York
$242K +$416K +62,578 New
Fidelity Investments
27
Fidelity Investments
Massachusetts
$241K -$13.2M -1,990,320 -97%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$211K -$307K -46,209 -46%
LP
29
LMR Partners
United Kingdom
$211K +$362K +54,539 New
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$186K -$70.9K -10,677 -18%
LPIC
31
LeJeune Puetz Investment Counsel
Michigan
$168K – – –
Charles Schwab
32
Charles Schwab
California
$145K -$203K -30,584 -45%
GCP
33
GSA Capital Partners
United Kingdom
$143K +$245K +36,972 New
PP
34
PDT Partners
New York
$142K -$203K -30,631 -45%
Citadel Advisors
35
Citadel Advisors
Florida
$126K +$216K +32,595 New
Balyasny Asset Management
36
Balyasny Asset Management
Illinois
$124K +$72.6K +10,930 +52%
Deutsche Bank
37
Deutsche Bank
Germany
$117K -$2.01M -303,461 -91%
Bank of America
38
Bank of America
North Carolina
$117K +$66.4K +10,005 +50%
Group One Trading
39
Group One Trading
Illinois
$113K +$191K +28,760 +5,426%
DTL
40
Dynamic Technology Lab
Singapore
$112K +$106K +15,931 +123%
SCM
41
Stonebridge Capital Management
California
$106K +$2.53K +381 +1%
BCM
42
BlueCrest Capital Management
Jersey
$102K +$175K +26,297 New
State Street
43
State Street
Massachusetts
$98K -$1.67M -252,239 -91%
Brown Advisory
44
Brown Advisory
Maryland
$98K – – –
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$97K +$167K +25,119 New
Barclays
46
Barclays
United Kingdom
$92K +$135K +20,385 +600%
Wolverine Trading
47
Wolverine Trading
Illinois
$91K – – –
AAMU
48
Amundi Asset Management US
Massachusetts
$77K +$18.6K +2,797 +16%
HighTower Advisors
49
HighTower Advisors
Illinois
$74K -$127K -19,065 -50%
KCM
50
Kempner Capital Management
Texas
$73K – – –
1
2
3 4

MACK Hedge Fund Activity: Q2 2018 in Review

76 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2018, worth a combined $31.4M — down 49% from $61.4M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of MACK and 17 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 21 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $9.37M. The largest seller was Fidelity Investments, cutting an estimated $13.2M.

  • 76 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2018, down from 81 in Q1 2018.
  • Funds reported $31.4M of Merrimack Pharmaceuticals, Inc. stock for Q2 2018, down 49% quarter-over-quarter.
  • 17 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2018 and 20 closed out, a net change of -3 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2018 was BVF Inc, an estimated $9.37M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2018 was Fidelity Investments, an estimated $13.2M sold.

Based on aggregated 13F filings for Q2 2018.